We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cohen & Steers’ (CNS - Free Report) third-quarter 2020 adjusted earnings of 67 cents per share surpassed the Zacks Consensus Estimate of 60 cents. Moreover, the bottom line was 3.1% higher than the year-ago reported figure.
Results primarily benefited from an improvement in revenues, partly offset by higher expenses. Despite net inflows, the company recorded a marginal fall in assets under management (AUM) balance.
Net income available to common stockholders (on a GAAP basis) was $31.9 million or 66 cents per share, down from $34 million or 70 cents per share in the prior-year quarter.
Revenues Improve & Expenses Rise
Revenues (GAAP basis) were $111.2 million, up 5.9% from the year-ago quarter. The rise was driven by an increase in investment advisory and administration fee.
Total expenses (GAAP basis) amounted to $67.9 million, up 4.7% year over year. All cost components, except for general and administrative expenses, witnessed a rise.
Operating income (GAAP basis) was $43.3 million, up 7.9% year over year.
Total non-operating income was $3.2 million, down 51.2% from the year-ago quarter.
AUM Falls Marginally
As of Sep 30, 2020, AUM was $70.5 billion, down marginally from the year-earlier quarter. The company’s net inflows were $2.3 billion in the reported quarter.
Average AUM totaled $69.8 billion, up 1.7% from the prior-year quarter.
Our Take
The company’s diverse product offerings and investment strategies will likely support top-line growth. Moreover, driven by a solid liquidity position, its capital deployments look sustainable.
Cohen Steers Inc Price, Consensus and EPS Surprise
Performance & Earnings Release Dates of Other Asset Managers
BlackRock, Inc.’s (BLK - Free Report) third-quarter 2020 adjusted earnings of $9.22 per share hugely surpassed the Zacks Consensus Estimate of $7.81. The figure reflected a rise of 29% from the year-ago quarter’s number.
Affiliated Managers Group, Inc. (AMG - Free Report) and Waddell & Reed Financial, Inc. are scheduled to announce quarterly results on Oct 26 and Oct 27, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Cohen & Steers (CNS) Q3 Earnings Beat, Revenues Rise Y/Y
Cohen & Steers’ (CNS - Free Report) third-quarter 2020 adjusted earnings of 67 cents per share surpassed the Zacks Consensus Estimate of 60 cents. Moreover, the bottom line was 3.1% higher than the year-ago reported figure.
Results primarily benefited from an improvement in revenues, partly offset by higher expenses. Despite net inflows, the company recorded a marginal fall in assets under management (AUM) balance.
Net income available to common stockholders (on a GAAP basis) was $31.9 million or 66 cents per share, down from $34 million or 70 cents per share in the prior-year quarter.
Revenues Improve & Expenses Rise
Revenues (GAAP basis) were $111.2 million, up 5.9% from the year-ago quarter. The rise was driven by an increase in investment advisory and administration fee.
Total expenses (GAAP basis) amounted to $67.9 million, up 4.7% year over year. All cost components, except for general and administrative expenses, witnessed a rise.
Operating income (GAAP basis) was $43.3 million, up 7.9% year over year.
Total non-operating income was $3.2 million, down 51.2% from the year-ago quarter.
AUM Falls Marginally
As of Sep 30, 2020, AUM was $70.5 billion, down marginally from the year-earlier quarter. The company’s net inflows were $2.3 billion in the reported quarter.
Average AUM totaled $69.8 billion, up 1.7% from the prior-year quarter.
Our Take
The company’s diverse product offerings and investment strategies will likely support top-line growth. Moreover, driven by a solid liquidity position, its capital deployments look sustainable.
Cohen Steers Inc Price, Consensus and EPS Surprise
Cohen Steers Inc price-consensus-eps-surprise-chart | Cohen Steers Inc Quote
Currently, Cohen & Steers carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance & Earnings Release Dates of Other Asset Managers
BlackRock, Inc.’s (BLK - Free Report) third-quarter 2020 adjusted earnings of $9.22 per share hugely surpassed the Zacks Consensus Estimate of $7.81. The figure reflected a rise of 29% from the year-ago quarter’s number.
Affiliated Managers Group, Inc. (AMG - Free Report) and Waddell & Reed Financial, Inc. are scheduled to announce quarterly results on Oct 26 and Oct 27, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>